Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Announces Internal Role Change for Chief Development and Operating Officer
Summary
On January 20, 2026, Crinetics Pharmaceuticals, Inc. announced a change in title and responsibilities for Jeff Knight, transitioning him from Chief Operating Officer to Chief Development and Operating Officer, effective January 2, 2026. This change reflects Mr. Knight's expanded duties and responsibilities within the company. Notably, there were no changes to his compensation arrangements or other agreements as detailed in the Company's 2025 Proxy Statement. The change in title is an internal restructuring aimed at aligning the company's operational and development strategies more closely.
Profitelligence Alerts
Get alerts for CRNX
Be first to know when Crinetics Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the development of novel therapeutics for patients with endocrine conditions and other rare diseases. The primary focus of Crinetics is on crafting oral therapies that target hormone receptors, offering significant potential to transform the treatment landscape for several disorders. The company's pipeline includes investigational drugs such as paltusotine and CRN04894, aimed at addressing conditions like acromegaly and congenital adrenal hyperplasia, respectively. Crinetics combines cutting-edge drug discovery with an in-depth understanding of disease biology to impact the field of endocrinology substantially. By specializing in small molecules, Crinetics Pharmaceuticals seeks to provide new treatment options that enhance patient quality of life and address significant unmet medical needs. Headquartered in San Diego, California, the enterprise collaborates with academic institutions and industry partners to position its innovations at the forefront of medical advancement. Its work holds significant potential to influence the pharmaceutical industry, contributing to the expansion of targeted therapies within niche markets where few options currently exist.
Official SEC Documents
Advertisement